both hypoglycaemia and high fasting plasma glucose were avoided by reducing the amount of short-acting insulin and increasing that of intermediate-acting insulin , so that the short-acting/intermediate-acting insulin ratio was significantly lower during bhi therapy , although the total daily insulin dose remained unchanged .
C0795635
bhi
C0021641
insulin